Activation Studies in Specific Disease States: Future Applications
In Chap. 9 we reviewed the exciting potential of SPET neuroactivation for understanding how the brain works in healthy controls. Despite this potential for studying normal brain function, SPET may possibly lag behind PET in this area over the next decade for several reasons. First, it is usually easier to label biologically active compounds with a radioactive carbon, nitrogen, fluoride or oxygen atom than it is to label them with single photon emitters such as 99mTc or 123I. Additionally, the shorter physical half-life of the tracers used in PET allow multiple images (6–10) to be taken of the same subject in a single activation session, thus increasing the statistical power to detect subtle functional changes. Of course, these are countered by the expense and relative non-availability of PET as we saw in Chaps. 1 and 2.
KeywordsRegional Cerebral Blood Flow Transient Ischaemic Attack Activation Protocol Specific Disease State Radioactive Carbon
Unable to display preview. Download preview PDF.
- Battisstin L, Pizzolato G, Dam M, et al (1989) Single-photon emission computed tomography studies with 99m-Tc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine. Eur Neurol 29:261–265Google Scholar
- Pilowski L, Costa DC, Kerwin R, et al (1991) Central D-2 dopaminergic receptor studies in treatment responsive and treatment resistant schizophrenia patients as measured by 123I-IBZM SPET (abstract). Schiz Res (in press)Google Scholar